AU2015335788B2 - Thiazolyl-containing compounds for treating proliferative diseases - Google Patents

Thiazolyl-containing compounds for treating proliferative diseases Download PDF

Info

Publication number
AU2015335788B2
AU2015335788B2 AU2015335788A AU2015335788A AU2015335788B2 AU 2015335788 B2 AU2015335788 B2 AU 2015335788B2 AU 2015335788 A AU2015335788 A AU 2015335788A AU 2015335788 A AU2015335788 A AU 2015335788A AU 2015335788 B2 AU2015335788 B2 AU 2015335788B2
Authority
AU
Australia
Prior art keywords
substituted
alkyl
unsubstituted
carbamate
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015335788A
Other languages
English (en)
Other versions
AU2015335788A1 (en
Inventor
Sara Jean Buhrlage
Hwan Geun Choi
Nathanael S. Gray
Steven P. Treon
Yuan Xiong
Guang Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2015335788A1 publication Critical patent/AU2015335788A1/en
Application granted granted Critical
Publication of AU2015335788B2 publication Critical patent/AU2015335788B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2015335788A 2014-10-22 2015-10-22 Thiazolyl-containing compounds for treating proliferative diseases Active AU2015335788B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462067178P 2014-10-22 2014-10-22
US62/067,178 2014-10-22
PCT/US2015/056899 WO2016065138A1 (en) 2014-10-22 2015-10-22 Thiazolyl-containing compounds for treating proliferative diseases

Publications (2)

Publication Number Publication Date
AU2015335788A1 AU2015335788A1 (en) 2017-05-04
AU2015335788B2 true AU2015335788B2 (en) 2020-07-30

Family

ID=55761545

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015335788A Active AU2015335788B2 (en) 2014-10-22 2015-10-22 Thiazolyl-containing compounds for treating proliferative diseases

Country Status (7)

Country Link
US (3) US10112957B2 (enExample)
EP (2) EP3715346B1 (enExample)
JP (1) JP6788583B2 (enExample)
AU (1) AU2015335788B2 (enExample)
CA (1) CA2965178C (enExample)
IL (1) IL251790B (enExample)
WO (1) WO2016065138A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9908872B2 (en) 2013-12-13 2018-03-06 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
AU2014361798B2 (en) 2013-12-13 2020-06-11 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
EP3715346B1 (en) 2014-10-22 2024-01-03 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
BR112018075086B1 (pt) * 2016-07-14 2024-02-27 Eli Lilly And Company Derivados de pirazolilaminobenzimidazol, seu uso, e composição farmacêutica
EP3534899B1 (en) 2016-11-03 2022-06-01 Corvus Pharmaceuticals, Inc. Compounds and methods for modulating interleukin-2-inducible t-cell kinase
KR102328682B1 (ko) * 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
CN109265455B (zh) * 2018-11-09 2020-08-18 新发药业有限公司 一种达沙替尼的制备方法
EP4112617A4 (en) * 2020-02-26 2024-03-13 Daewoong Pharmaceutical Co., Ltd. PROCESS FOR PREPARING HETEROCYCLIC AMINE DERIVATIVES
JP7691991B2 (ja) * 2020-03-06 2025-06-12 ナショナル・ヘルス・リサーチ・インスティテューツ ピリミジン化合物及びその薬学的使用
WO2024111626A1 (ja) * 2022-11-25 2024-05-30 カルナバイオサイエンス株式会社 新規チアゾール誘導体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081172A2 (en) * 2005-01-26 2006-08-03 Irm Llc Compounds and compositions as protein kinase inhibitors

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
ATE269295T1 (de) 1998-04-17 2004-07-15 Parker Hughes Inst Btk inhibitoren und verfahren zur identifizierung und verwendung
BR9912729A (pt) 1998-08-04 2001-05-02 Astrazeneca Ab Derivado de amida, processo para prepará-lo, e, uso do mesmo
AU761361B2 (en) 1998-09-25 2003-06-05 Astrazeneca Ab Benzamide derivatives and their use as cytokine inhibitors
US6306897B1 (en) 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
ATE511840T1 (de) 2001-10-09 2011-06-15 Amgen Inc Imidazolderivate als entzündungshemmende mittel
RU2005106871A (ru) 2002-08-14 2005-10-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы протеинкиназ и их применение
ES2571779T3 (es) 2002-12-13 2016-05-26 Ym Biosciences Australia Pty Inhibidores de cinasa a base de nicotinamida
WO2006067445A2 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
CA2589773A1 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Pyridine carboxamide derivatives for use as anticancer agents
US7375951B2 (en) * 2006-07-07 2008-05-20 Lutron Electronics Co., Inc. Load control device having a split enclosure
US7605154B2 (en) 2005-08-08 2009-10-20 Janssen Pharmaceutica N.V. Substituted Thiazolo [4,5-d]pyrimidines as protein kinase inhibitors
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
JP5225857B2 (ja) 2005-11-14 2013-07-03 ジェネンテック，インコーポレイティド ヘッジホッグシグナル伝達のビスアミド阻害剤
US20070155746A1 (en) 2005-12-23 2007-07-05 Kalypsys, Inc. Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
US20090312396A1 (en) 2006-07-10 2009-12-17 Astrazeneca Ab Methods for cancer treatment using tak1 inhibitors
EP2526934B1 (en) 2006-09-22 2015-12-09 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
TW200906825A (en) * 2007-05-30 2009-02-16 Scripps Research Inst Inhibitors of protein kinases
TW200911798A (en) 2007-08-02 2009-03-16 Amgen Inc PI3 kinase modulators and methods of use
KR20120033357A (ko) 2007-10-23 2012-04-06 테바 파마슈티컬 인더스트리즈 리미티드 다사티닙 다형체 및 이의 제조 방법
WO2009076373A1 (en) 2007-12-10 2009-06-18 Concert Pharmaceuticals Inc. Heterocyclic kinase inhibitors
WO2009137596A1 (en) 2008-05-06 2009-11-12 Cgi Pharmaceuticals, Inc. Substituted amides, method of making, and use as btk inhibitors
CA2735208A1 (en) 2008-09-02 2010-03-11 Boehringer Ingelheim International Gmbh Novel benzamides, production thereof, and use thereof as medicaments
WO2010056875A1 (en) 2008-11-12 2010-05-20 Cgi Pharmaceuticals, Inc. Pyridazinones and their use as btk inhibitors
IN2012DN02493A (enExample) 2009-09-03 2015-08-28 Allergan Inc
EP2485589A4 (en) 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYL-BTK INHIBITORS
CA2784807C (en) * 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
KR101995013B1 (ko) 2010-07-13 2019-07-02 에프. 호프만-라 로슈 아게 Irak4 조절제로서 피라졸로[1,5a]피리미딘 및 티에노[3,2b]피리미딘 유도체
WO2012062704A1 (en) 2010-11-09 2012-05-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
WO2012068096A2 (en) 2010-11-15 2012-05-24 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
PL2714677T3 (pl) 2011-05-23 2019-02-28 Merck Patent Gmbh Pochodne pirydynowe i pirazynowe
KR20180084153A (ko) * 2011-06-10 2018-07-24 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
EP2763966B1 (en) 2011-10-03 2018-04-04 Syngenta Participations AG Insecticidal 2-methoxybenzamide derivatives
CA2850763A1 (en) 2011-10-04 2013-04-11 Gilead Calistoga Llc Novel quinoxaline inhibitors of pi3k
SG11201401993RA (en) 2011-11-03 2014-05-29 Hoffmann La Roche Alkylated piperazine compounds as inhibitors of btk activity
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
CA2857302C (en) 2011-12-15 2020-08-25 Novartis Ag Use of inhibitors of the activity or function of pi3k
CN103405429A (zh) 2013-08-22 2013-11-27 中国药科大学 一类vegfr-2抑制剂及其用途
WO2015069287A1 (en) 2013-11-08 2015-05-14 Allergan, Inc. Compounds as tyrosine kinase modulators
US9908872B2 (en) 2013-12-13 2018-03-06 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
AU2014361798B2 (en) 2013-12-13 2020-06-11 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
EP3715346B1 (en) 2014-10-22 2024-01-03 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081172A2 (en) * 2005-01-26 2006-08-03 Irm Llc Compounds and compositions as protein kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRANK E. KWARCINSKI ET AL, "Irreversible Inhibitors of c-Src Kinase That Target a Nonconserved Cysteine", ACS CHEMICAL BIOLOGY, US, 2012, vol. 7, no. 11, pages 1910 - 1917 *

Also Published As

Publication number Publication date
EP3715346A1 (en) 2020-09-30
EP3715346B1 (en) 2024-01-03
EP3209648B1 (en) 2020-03-11
CA2965178A1 (en) 2016-04-28
US20200165267A1 (en) 2020-05-28
CA2965178C (en) 2023-09-26
US20170233411A1 (en) 2017-08-17
EP3209648A1 (en) 2017-08-30
IL251790A0 (en) 2017-06-29
EP3209648A4 (en) 2018-07-25
JP6788583B2 (ja) 2020-11-25
IL251790B (en) 2019-08-29
WO2016065138A1 (en) 2016-04-28
AU2015335788A1 (en) 2017-05-04
JP2017537886A (ja) 2017-12-21
US10112957B2 (en) 2018-10-30
US10844077B2 (en) 2020-11-24
US10464949B2 (en) 2019-11-05
US20190119301A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
AU2015335788B2 (en) Thiazolyl-containing compounds for treating proliferative diseases
AU2016283105B2 (en) 4,6-pyrimidinylene derivatives and uses thereof
US20210261551A9 (en) Inhibitors of cyclin-dependent kinases
JP6854762B2 (ja) サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
US10342798B2 (en) Fused bicyclic pyrimidine derivatives and uses thereof
US20230151001A9 (en) Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
AU2019413694B2 (en) Inhibitors of cyclin-dependent kinase 7 and uses thereof
US20220127246A1 (en) Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
AU2020357983B2 (en) Tricyclic kinase inhibitors and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)